Literature DB >> 24325385

Paradoxical effects of anti-TNF-α agents in inflammatory diseases.

Daniel Wendling1, Clément Prati.   

Abstract

Anti-TNF agents represent a major breakthrough in the management of inflammatory diseases. Among the side effects of these agents are the so-called paradoxical effects described in this review. They represent new onset or exacerbation of a condition (symptom/disease), usually improved with TNF blockers. These paradoxical effects are mainly psoriasiform skin reactions, uveitis and granulomatous diseases (such as sarcoidosis and Crohn's disease). Infrequent and probably underreported, they should be discussed from the viewpoint of spontaneous features of the underlying disease (e.g., uveitis or psoriasis in a case of spondyloarthritis). The causal mechanism of occurrence is still a matter of debate, but may implicate an imbalance of cytokines toward interferons, chemokines and probably IL-17. These reactions may raise differential diagnosis problems. Symptoms resolve, most of the time, due to the discontinuation of the anti-TNF agent or sometimes a switch to another TNF blocker; but in some cases, it is a class effect that could lead to the withdrawal of all anti-TNF agents.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24325385     DOI: 10.1586/1744666X.2014.866038

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   4.473


  27 in total

1.  Activated human Foxp3+ regulatory T cells produce membrane-bound TNF.

Authors:  Alexander Nelson; Christina Cunha; Michael I Nishimura; Makio Iwashima
Journal:  Cytokine       Date:  2018-06-06       Impact factor: 3.861

2.  Response: Leflunomide: potential treatment and cause of alopecia areata.

Authors:  Greg Koller; Jill Hall; Carrie Ye
Journal:  Clin Rheumatol       Date:  2019-07-23       Impact factor: 2.980

Review 3.  Inflammatory Joint Disorders and Neutrophilic Dermatoses: a Comprehensive Review.

Authors:  Massimo Cugno; Roberta Gualtierotti; Pier Luigi Meroni; Angelo Valerio Marzano
Journal:  Clin Rev Allergy Immunol       Date:  2018-04       Impact factor: 8.667

Review 4.  Remicade® (infliximab): 20 years of contributions to science and medicine.

Authors:  Richard Melsheimer; Anja Geldhof; Isabel Apaolaza; Thomas Schaible
Journal:  Biologics       Date:  2019-07-30

Review 5.  [Musculoskeletal manifestations of sarcoidosis].

Authors:  P Korsten; G Chehab
Journal:  Z Rheumatol       Date:  2017-06       Impact factor: 1.372

6.  Takayasu's arteritis occurring under TNF-α blockers: a new paradoxical effect?

Authors:  Leila Souabni; Kaouther Ben Abdelghani; Saoussen Jradi; Leith Zakraoui
Journal:  BMJ Case Rep       Date:  2014-11-24

7.  Reduced skin blistering in experimental epidermolysis bullosa acquisita after anti-TNF treatment.

Authors:  Misa Hirose; Anika Kasprick; Foteini Beltsiou; Katharina Dieckhoff Schulze; Franziska Sophine Schulze; Unni Kjsrl Samavedam; Jennifer E Hundt; Hendri H Pas; Marcel F Jonkman; Enno Schmidt; Kathrin Kalies; Detlef Zillikens; Ralf J Ludwig; Katja Bieber
Journal:  Mol Med       Date:  2016-12-20       Impact factor: 6.354

8.  Paradoxical psoriasiform reactions to anti-TNFα drugs are associated with genetic polymorphisms in patients with psoriasis.

Authors:  T Cabaleiro; R Prieto-Pérez; R Navarro; G Solano; M Román; D Ochoa; F Abad-Santos; E Daudén
Journal:  Pharmacogenomics J       Date:  2015-07-21       Impact factor: 3.550

9.  Preventive effect of tumor necrosis factor inhibitors versus nonsteroidal anti-inflammatory drugs on uveitis in patients with ankylosing spondylitis.

Authors:  Min Jung Kim; Eunyoung Emily Lee; Eun Young Lee; Yeong Wook Song; Hyeong Gon Yu; Yunhee Choi; Eun Bong Lee
Journal:  Clin Rheumatol       Date:  2018-08-04       Impact factor: 2.980

10.  A Rare Adverse Effect of Anti-Tumor Necrosis Factor Alpha Therapy: Sarcoidosis.

Authors:  Gönen Mengi; Feride Göğüş
Journal:  Arch Rheumatol       Date:  2017-02-12       Impact factor: 1.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.